ArticleOrthopaedic surgery2024

A Real-world Study of Denosumab For Reducing Refracture Risk after Percutaneous Vertebral Augmentation.

Jun Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.